Embriopatía por isotretinoína: Una entidad que puede evitarse

Translated title of the contribution: Isotretinoin embryopathy: An entity that can be avoided

Francisco Cammarata-Scalisi, Dairelis Nieves, Andrea Avendaño, María A Lacruz-Rengel, Karelys Alviárez, Francys Dávila, Izzet Yavuz, Michele Callea

Research output: Contribution to journalArticle

Abstract

Isotretinoin is the most effective drug in the treatment of severe recalcitrant nodulocystic acne. However, treatment with this drug is associated with adverse effects, the most severe being teratogenesis. It has been estimated that 40% of pregnancies exposed to isotretinoin present spontaneous abortion and 35% develop embryopathy. We present the case of a newborn with a history of prenatal exposure to isotretinoin, a clinical entity that can be avoided, with severe congenital defects in the central nervous system and important facial dysmorphisms, with unfavorable clinical course.

Original languageSpanish
Pages (from-to)e303-e307
Number of pages5
JournalArchivos Argentinos de Pediatria
Volume116
Issue number2
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Isotretinoin
Teratogenesis
Fetal Diseases
Acne Vulgaris
Spontaneous Abortion
Pharmaceutical Preparations
Central Nervous System
Pregnancy
Accutane embryopathy

Cite this

Cammarata-Scalisi, F., Nieves, D., Avendaño, A., Lacruz-Rengel, M. A., Alviárez, K., Dávila, F., ... Callea, M. (2018). Embriopatía por isotretinoína: Una entidad que puede evitarse. Archivos Argentinos de Pediatria, 116(2), e303-e307. https://doi.org/10.5546/aap.2018.e303

Embriopatía por isotretinoína : Una entidad que puede evitarse. / Cammarata-Scalisi, Francisco; Nieves, Dairelis; Avendaño, Andrea; Lacruz-Rengel, María A; Alviárez, Karelys; Dávila, Francys; Yavuz, Izzet; Callea, Michele.

In: Archivos Argentinos de Pediatria, Vol. 116, No. 2, 01.04.2018, p. e303-e307.

Research output: Contribution to journalArticle

Cammarata-Scalisi, F, Nieves, D, Avendaño, A, Lacruz-Rengel, MA, Alviárez, K, Dávila, F, Yavuz, I & Callea, M 2018, 'Embriopatía por isotretinoína: Una entidad que puede evitarse', Archivos Argentinos de Pediatria, vol. 116, no. 2, pp. e303-e307. https://doi.org/10.5546/aap.2018.e303
Cammarata-Scalisi F, Nieves D, Avendaño A, Lacruz-Rengel MA, Alviárez K, Dávila F et al. Embriopatía por isotretinoína: Una entidad que puede evitarse. Archivos Argentinos de Pediatria. 2018 Apr 1;116(2):e303-e307. https://doi.org/10.5546/aap.2018.e303
Cammarata-Scalisi, Francisco ; Nieves, Dairelis ; Avendaño, Andrea ; Lacruz-Rengel, María A ; Alviárez, Karelys ; Dávila, Francys ; Yavuz, Izzet ; Callea, Michele. / Embriopatía por isotretinoína : Una entidad que puede evitarse. In: Archivos Argentinos de Pediatria. 2018 ; Vol. 116, No. 2. pp. e303-e307.
@article{7aece9b5f7a64485a6bc9a08cdb8fd5d,
title = "Embriopat{\'i}a por isotretino{\'i}na: Una entidad que puede evitarse",
abstract = "Isotretinoin is the most effective drug in the treatment of severe recalcitrant nodulocystic acne. However, treatment with this drug is associated with adverse effects, the most severe being teratogenesis. It has been estimated that 40{\%} of pregnancies exposed to isotretinoin present spontaneous abortion and 35{\%} develop embryopathy. We present the case of a newborn with a history of prenatal exposure to isotretinoin, a clinical entity that can be avoided, with severe congenital defects in the central nervous system and important facial dysmorphisms, with unfavorable clinical course.",
author = "Francisco Cammarata-Scalisi and Dairelis Nieves and Andrea Avenda{\~n}o and Lacruz-Rengel, {Mar{\'i}a A} and Karelys Alvi{\'a}rez and Francys D{\'a}vila and Izzet Yavuz and Michele Callea",
note = "Sociedad Argentina de Pediatr{\'i}a.",
year = "2018",
month = "4",
day = "1",
doi = "10.5546/aap.2018.e303",
language = "Spagnolo",
volume = "116",
pages = "e303--e307",
journal = "Archivos Argentinos de Pediatria",
issn = "0325-0075",
publisher = "Sociedad Argentina de Pediatria",
number = "2",

}

TY - JOUR

T1 - Embriopatía por isotretinoína

T2 - Una entidad que puede evitarse

AU - Cammarata-Scalisi, Francisco

AU - Nieves, Dairelis

AU - Avendaño, Andrea

AU - Lacruz-Rengel, María A

AU - Alviárez, Karelys

AU - Dávila, Francys

AU - Yavuz, Izzet

AU - Callea, Michele

N1 - Sociedad Argentina de Pediatría.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Isotretinoin is the most effective drug in the treatment of severe recalcitrant nodulocystic acne. However, treatment with this drug is associated with adverse effects, the most severe being teratogenesis. It has been estimated that 40% of pregnancies exposed to isotretinoin present spontaneous abortion and 35% develop embryopathy. We present the case of a newborn with a history of prenatal exposure to isotretinoin, a clinical entity that can be avoided, with severe congenital defects in the central nervous system and important facial dysmorphisms, with unfavorable clinical course.

AB - Isotretinoin is the most effective drug in the treatment of severe recalcitrant nodulocystic acne. However, treatment with this drug is associated with adverse effects, the most severe being teratogenesis. It has been estimated that 40% of pregnancies exposed to isotretinoin present spontaneous abortion and 35% develop embryopathy. We present the case of a newborn with a history of prenatal exposure to isotretinoin, a clinical entity that can be avoided, with severe congenital defects in the central nervous system and important facial dysmorphisms, with unfavorable clinical course.

U2 - 10.5546/aap.2018.e303

DO - 10.5546/aap.2018.e303

M3 - Articolo

C2 - 29557621

VL - 116

SP - e303-e307

JO - Archivos Argentinos de Pediatria

JF - Archivos Argentinos de Pediatria

SN - 0325-0075

IS - 2

ER -